← Eichor
Study identifier: NCT04802603 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Dose-Escalated Spine SbRT for Localized Metastasis to the Spinal Column

Condition: Spine Metastases · Metastasis Spine  ·  Sponsor: Baptist Health South Florida

PhaseNA
Planned participants60
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study is being done to determine the feasibility and tolerability of a novel regimen of spine stereotactic radiosurgery (SSRS). SSRS delivers high doses of radiation to tumors of the spine using precision techniques. In standard medical care, conventional SSRS is delivered in only 1 or 2 treatments. When this treatment is delivered in only 1-2 treatments, a high dose is used which can increase the side effects of treatment. This study aims to test an alternative technique of delivering SSRS over 5 treatments. By delivering the radiation therapy over multiple treatments, the dose of radiation is less per treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Rupesh Kotecha, MD  ·  786-596-2000  ·  RupeshK@baptisthealth.net

Antoinette Pimentel  ·  17865962000  ·  antoinette.pimentel@baptisthealth.net

Always discuss trial participation with your own doctor first.

Locations (1)

Miami Cancer Institute at Baptist Health, IncMiami, Florida, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04802603